Bolder Biotechnology, Inc.

Sangamo Biosciences, Inc.

Indiana University

The Medical College of Wisconsin, Inc.

George N Cox

Casey Christopher Case

Stephen P Eisenberg

Eric E Jarvis

Daniel H Doherty

Mary S Rosendahl

Sharon Kaye Spratt

Christie M Orschell

Edward J Rebar

Andrew Jamieson

Brian Fish

Meetha Manek Medhora

Qiang Liu

Daniel J Doherty

Methods and compositions comprising hematopoietic growth factor proteins and/or protein analogs thereof and/or combinations thereof and angiotensin converting enzyme inhibitors to treat the acute and long term adverse effects of radiation exposure in subjects who have been or will be exposed to radiation are disclosed.

Hematopoietic growth factor proteins and analogs thereof and angiotensin converting enzyme inhibitors for treatment of radiation exposure

Methods and compositions for the use of long-acting hematopoietic factor protein analogs for accelerating hematopoietic recovery in subjects who have been or will be exposed to radiation are disclosed.

Methods and use of growth hormone supergene family protein analogs for treatment of radiation exposure

Disclosed is a method for refolding a protein or peptide that does not contain essential disulfides and that contains at least one free cysteine residue. Also disclosed are polymer IFN-&#x3b3; conjugates that have been created by the chemical coupling of polymers such as polyethylene glycol moieties to IFN-&#x3b3;, particularly via a free cysteine in the protein. Also disclosed are analogs of bioactive peptides that may be used to create longer acting versions of the peptides, including analogs of glucagon, glucagon-like peptide-1 (GLP-1), GLP-2, Gastric inhibitory peptide (GIP), PYY, exendin, ghrelin, gastrin, amylin, and oxyntomodulin.

Cysteine analogs of exendin-4

Disclosed are cysteine variants of interleukin-11 (IL-11) and methods of making and using such proteins in therapeutic applications.

Method to increase the number of circulating platelets by administering PEGylated cysteine variants of IL-11

Methods of preparing cysteine variants of human recombinant IL-11

The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins.

Regulation of endogenous gene expression in cells using zinc finger proteins

NH2-terminal glutamine modified cysteine variants of interferon gamma

The present invention relates to novel methods of making soluble proteins having free cysteines in which a host cell is exposed to a cysteine blocking agent. The soluble proteins produced by the methods can then be modified to increase their effectiveness. Such modifications include attaching a PEG moiety to form pegylated proteins.

Methods for making proteins containing free cysteine residues

The present invention relates to novel methods for making and refolding insoluble or aggregated proteins having free cysteines in which a host cell expressing the protein is exposed to a cysteine blocking agent. The soluble, refolded proteins produced by the novel methods can then be modified to increase their effectiveness. Such modifications include attaching a PEG moiety to form PEGylated proteins.

Method for preparing recombinant granulocyte colony stimulating factor cysteine muteins

The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby. Also disclosed are therapeutic methods for using the cysteine variants of the invention.

Method of treatment using cysteine mutants of beta interferon

Methods of treatment using cysteine variants of interleukin-11

The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby.

Growing community of inventors

Louisville, CO, United States of America

George N Cox